• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Investors May Respond To Takeda (TSE:4502) Phase 3 Psoriasis Win

    Simply Wall St·10/13/2026 21:38:24
    Listen to the news
    • Takeda Pharmaceutical reported Phase 3 data for zasocitinib in adults with moderate to severe plaque psoriasis, where the oral TYK2 inhibitor achieved higher complete skin clearance rates than deucravacitinib and met all key endpoints across three LATITUDE studies.
    • The psoriasis results add another potential anchor asset alongside Takeda Pharmaceutical's broader immune mediated pipeline, since zasocitinib is already in late stage programs across psoriatic arthritis, inflammatory bowel disease, vitiligo and hidradenitis suppurativa.
    • The focus now turns to how Takeda Pharmaceutical's investment narrative could be reshaped by zasocitinib's head to head superiority over deucravacitinib.

    Scan beyond Takeda Pharmaceutical and see how other potential breakout candidates in healthcare stack up using our curated list of 9 healthcare AI stocks.

    Takeda Pharmaceutical Investment Narrative Recap

    To own Takeda Pharmaceutical, you need to believe the late stage pipeline can gradually offset pressure from generics and biosimilars while the group works back toward consistent profitability. The zasocitinib psoriasis data sits in the middle of that story because it supports the case that new specialty products can matter for the mix.

    The most visible near term catalyst now is regulatory outcome and launch execution for zasocitinib in plaque psoriasis, alongside its upcoming readouts in other immune mediated conditions. The biggest risk is that even with positive data and approvals, real world uptake and pricing do not bridge the gap left by loss of exclusivity on older therapies.

    The EADV 2026 readout from the LATITUDE Phase 3 program is the key announcement tied to this catalyst. Takeda Pharmaceutical showed zasocitinib beating deucravacitinib on the primary endpoint of complete skin clearance at week 16, with 36.5% of patients on zasocitinib reaching PASI 100 compared with 13.9% on the comparator.

    That efficacy profile, together with consistency against apremilast in the other LATITUDE studies, gives management a concrete data package as regulators review psoriasis filings in the US and Europe. For investors, the focus now is on timing and quality of launches, how quickly physicians adopt an oral TYK2 option, and whether ongoing trials in psoriatic arthritis and inflammatory bowel disease keep the broader franchise on track.

    Takeda Pharmaceutical's current analyst narrative connects forecast revenues of ¥4,989.8b and projected earnings of ¥401.8b by 2029. These figures are based on an assumed 2.6% yearly revenue growth rate and a swing in profit from an earnings loss of ¥163.4b today to those forecast earnings, which implies an earnings increase of about ¥565b over the period.

    Uncover why Takeda Pharmaceutical's fair value indicates an 11% potential upside to its current price before the market closes that gap.

    TSE:4502 1-Year Stock Price Chart
    TSE:4502 1-Year Stock Price Chart

    Exploring Other Perspectives

    Some of the most optimistic analysts already framed Takeda Pharmaceutical around new launches offsetting ENTYVIO pressure, with forecasts reaching ¥5,072.4b in revenue and ¥423.0b in earnings by 2029. Those views were set before this psoriasis data. You now get to compare that optimism with the fresh zasocitinib results and decide whether expectations might shift.

    Explore 2 other Takeda Pharmaceutical fair value estimates, including one that suggests as much as 141% potential upside from the current price!

    Reach Your Own Conclusion

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider trusting your own analysis.

    Looking For More Investment Ideas Beyond Takeda Pharmaceutical?

    If the Takeda Pharmaceutical story has sharpened your thinking about risk, timing, and pricing power, you can use that same lens to look for other opportunities across the market with the Simply Wall St Screener.

    • For investors who want income at the forefront, review a focused set of companies that currently show up as 27 dividend fortresses and see which yields appear sustainable based on the available numbers.
    • If capital protection is the priority, start with businesses that currently screen as 24 resilient stocks with low risk scores and compare their balance sheet strength, earnings consistency, and volatility with what you see in Takeda Pharmaceutical.
    • When the goal is to find potential future leaders before they become crowded trades, scan through 74 high quality undiscovered gems and look for fundamentals that align with your return and risk preferences.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.